14 results about "Viral Myocarditis" patented technology

The invention discloses application of piperlongumine in preparation of a medicine for treating virus-induced myocardial fibrosis. According to the application, an in-vivo myocardial fibrosis model is constructed by infecting a BALB / c mouse with a CVB3 virus, and meanwhile, an in-vitro cell model for proliferation and differentiation of primary myocardial fibroblasts is constructed by inducing TGF-beta1. Results prove that when the piperlongumine is applied to the acute stage (1-14 days), the chronic stage (14-28 days) and the whole course (1-28 days) of the viral myocarditis, the myocardial fibrosis of the viral myocarditis can be remarkably improved, the cardiac function is improved, and the curative effect of the piperlongumine applied to the whole course is superior to that of the piperlongumine applied to the acute stage and the chronic stage; the specific mechanism is that Smad2 / 3 and p-38 / YAP pathways jointly play a role in inhibiting myocardial fibrosis.

This invention provides a traditional Chinese medicine compound for treating viral myocarditis, belonging to the field of traditional Chinese medicine pharmaceutical technology. The compound consists of Forsythia suspensa, Fagopyrum dibotrys, Pseudostellaria heterophylla, Rhodiola rosea, Citrus medica, Allium macrostemon, Poria cocos, Gynostemma pentaphyllum, Salvia miltiorrhiza, Dalbergia odorifera, Cynanchum paniculatum, and Valeriana. This traditional Chinese medicine compound exhibits significant protective effects against viral myocarditis, specifically by significantly reducing damage to H9c2 cardiomyocytes caused by CVB3 virus. Its mechanism of action is closely related to downregulating the expression of inflammatory factors TNF-α and IL-6 and inhibiting the inflammatory response. Simultaneously, within the experimental concentration range, the compound shows no toxicity to cardiomyocytes, demonstrating good biocompatibility. Furthermore, this compound can significantly reduce myocardial tissue damage in a viral myocarditis model mouse by inhibiting the in vivo inflammatory response and regulating oxidative stress imbalance, providing a safe and effective new treatment option for the clinical treatment of viral myocarditis.

The invention belongs to the technical field of biological medicines, and particularly discloses application of rosmarinic acid (RA) in treatment of viral myocarditis caused by group B type 3 coxsackie virus (CVB3). Mouse animal model research finds that the rosmarinic acid can significantly reduce the virus load in CVB3 infected mouse cardiac muscle tissue, and proves that the rosmarinic acid has the effect of inhibiting CVB3 virus replication; meanwhile, the treatment can obviously improve cardiac function impairment caused by CVB3 virus infection and relieve inflammatory response of cardiac muscle tissue, and the release of key inflammatory factors and myocardial injury factors is reduced. The invention provides an experimental basis for treating viral myocarditis by using rosmarinic acid as an anti-CVB3 virus drug.

To provide a bifunctional degrading agent for interleukin-1 receptor-related kinases and its therapeutic use. [Solution] This disclosure provides a bifunctional compound as an IRAK4 degradation agent via the ubiquitin-proteasome pathway, and a method for treating diseases modulated by IRAK4. The compounds of this disclosure or their pharmaceutical compositions are useful as therapeutic agents for treating inflammatory disorders such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, necrotizing enterocolitis, gout, Lyme disease, arthritis, psoriasis, pelvic inflammatory disease, systemic lupus erythematosus (SLE), Sjögren's syndrome, inflammation associated with gastrointestinal infections including C. difficile, viral myocarditis, acute and chronic tissue injury, non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, and renal diseases including chronic kidney disease and diabetic kidney disease.

The application provides the technical field of biological medicine, and particularly relates to BAZ2B The application provides application of a gene in preparation of a preparation for regulating viral myocarditis. BAZ2B The gene can be applied in preparation of the preparation for regulating viral myocarditis, and the BAZ2B inhibitor GSK2801 can effectively treat viral myocarditis.

The application discloses a kit for detecting coxsackie virus B3, which comprises: an RNA extraction and reverse transcription system, an MIRA isothermal amplification system, a CRISPR-Cas12a detection system, a test strip, and the like. The kit is convenient to operate, can quickly and sensitively detect coxsackie virus B3 in a biological sample, and is used for improving the diagnosis efficiency of viral myocarditis.

The invention discloses a humanized monoclonal antibody of a beta1-adrenergic receptor as well as a kit and application of the humanized monoclonal antibody. The amino acid sequence of the humanized monoclonal antibody of the beta1-adrenergic receptor is as shown in SEQ ID No.1. The invention further discloses a preparation method of the humanized monoclonal antibody of the beta1-adrenergic receptor. According to the distribution condition of myocardial antigenic determinants, polypeptides of natural antigenic determinants are designed and synthesized to immunize animals to prepare monoclonal antibodies and carry out humanized expression, so that the antibody detection kit is prepared. The kit can be used for auxiliary diagnosis of autoimmune response activation and prognosis judgment of patients with viral myocarditis and dilated cardiomyopathy, and auxiliary establishment of a patient treatment scheme.

The invention belongs to the technical field of biology, and particularly relates to application of PDPN (Podoplanin) in preparation of a medicine for treating viral myocarditis. More specifically, the invention provides a novel immunogenic peptide fragment PDPN-TE12 aiming at PDPN, a coding sequence of the novel immunogenic peptide fragment PDPN-TE12, a pharmaceutical composition containing the novel immunogenic peptide fragment PDPN-TE12, and application of the novel immunogenic peptide fragment PDPN-TE12 in prevention and / or treatment of inflammatory cardiomyopathy such as viral myocarditis. Experimental results show that the polypeptide PDPN-TE12 can significantly relieve myocardial damage of mice with viral myocarditis and inhibit inflammatory cell infiltration and inflammatory cytokine expression, so that the polypeptide PDPN-TE12 can be used as a potential drug for treating viral myocarditis, and a new candidate strategy is provided for precise targeted therapy of the disease.

This invention discloses a drug for viral myocarditis, relating to the field of drug preparation technology. The drug comprises at least one of imperatorin, isochorin, and epicatechin gallate. This drug can effectively inhibit viral replication in myocardial tissue, significantly reduce serum pro-inflammatory factor levels, alleviate inflammatory infiltration, and significantly reduce cell apoptosis, thereby exerting a therapeutic effect on viral myocarditis. This invention solves the problem of the lack of highly effective multi-target viral myocarditis drugs in the prior art.

The invention discloses a humanized monoclonal antibody of an L-type calcium channel as well as a kit and application of the humanized monoclonal antibody, the humanized monoclonal antibody comprises a heavy chain and a light chain, and amino acid sequences of the heavy chain and the light chain are respectively shown as SEQ ID No.1 and SEQ ID No.2; according to the distribution condition of myocardial antigenic determinants, a polypeptide of a natural antigenic determinant, namely an L-type calcium channel antigen, is designed and synthesized, an animal is immunized to prepare a monoclonal antibody, humanized expression is carried out, and the antibody detection kit is prepared from the monoclonal antibody for application. The kit can be used for auxiliary diagnosis of viral myocarditis and dilated cardiomyopathy and auxiliary establishment of a patient treatment scheme.

This disclosure relates, in general, to a process for preparing compounds that are inhibitors of the kinase IRAK4, and to synthetic intermediates prepared thereby. IRAK4 inhibitors may be useful in the treatment of inflammatory and fibrous disorders, such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), gout, Lyme disease, arthritis, psoriasis, pelvic inflammatory disease, systemic lupus erythematosus (SLE), Sjögren's syndrome, inflammation associated with gastrointestinal infections including C. difficile, viral myocarditis, acute and chronic tissue injury, non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, and renal diseases, including chronic kidney disease and diabetic kidney disease.

The invention provides a traditional Chinese medicine compound for treating viral myocarditis, and relates to the technical field of traditional Chinese medicine pharmacy, and the traditional Chinese medicine compound consists of fructus forsythiae, wild buckwheat, radix pseudostellariae, rhodiola rosea, citron, allium macrostemon, poria cocos, Chinese alpine rush, semen aesculi, lignum dalbergiae odoriferae, radix cynanchi atrati and valerian. The traditional Chinese medicine compound has a remarkable protective effect on viral myocarditis, specifically, the compound can remarkably relieve H9c2 myocardial cell damage caused by CVB3 virus, and the action mechanism of the compound is closely related to down-regulation of expression of inflammatory factors TNF-alpha and IL-6 and inhibition of inflammatory response; meanwhile, within the experimental concentration range, the compound has no toxic effect on myocardial cells and shows good biological safety. Besides, the compound can remarkably relieve myocardial tissue damage of viral myocarditis model mice by inhibiting inflammatory response in vivo and adjusting oxidative stress imbalance, and a safe and effective new treatment scheme is provided for clinical treatment of viral myocarditis.

The application discloses use of let-7a-5p in human umbilical cord mesenchymal stem cell exosomes, and relates to the technical field of biological medicines, and has the technical points that the let-7a-5p in the human umbilical cord mesenchymal stem cell exosomes is applied to preparation of a medicine for treating viral myocarditis; the let-7a-5p in the exosomes inhibits CVB3-induced myocardial cell ferroptosis through mediation of SMAD2 to promote a ZFP36 expression path, so that viral myocarditis is treated. The application proves how the let-7a-5p in the human umbilical cord mesenchymal stem cell exosomes relieves the process of CVB3-induced viral myocarditis, and provides a new and effective treatment method according to the mechanism of CVB3-induced viral myocarditis.

The invention belongs to the technical field of biological medicines, and particularly discloses application of abietic acid (AA) in treatment of viral myocarditis caused by group B type 3 coxsackie virus (CVB3). Mouse animal model research finds that abietic acid can significantly reduce the virus load in CVB3 infected mouse cardiac muscle tissue, and proves that abietic acid has the effect of inhibiting CVB3 virus replication; meanwhile, the treatment can obviously improve cardiac function impairment caused by CVB3 virus infection and relieve inflammatory response of cardiac muscle tissue, and the release of key inflammatory factors and myocardial injury factors is reduced. The invention provides an experimental basis for treating viral myocarditis by using abietic acid as an anti-CVB3 virus drug.